Latest On OptiNose, Inc (OPTN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 23:19 EST | News | OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-11 09:05 EST | News | OptiNose GAAP EPS of -$0.17, revenue of $11.85M | N/A | |
| 2023-05-04 15:23 EST | News | Optinose gets FDA review for expanded use of Xhance for chronic rhinosinusitis | N/A | |
| 2023-03-07 23:01 EST | News | OptiNose, Inc. (OPTN) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-07 08:15 EST | News | OptiNose GAAP EPS of -$0.17 in-line, revenue of $20.86M beats by $0.17M | N/A | |
About OptiNose, Inc (OPTN):
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale product read more...s containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
General
- Name OptiNose, Inc
- Symbol OPTN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 204
- Fiscal Year EndDecember
- IPO Date2017-10-13
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.optinose.com
Valuation
- Price/Sales (Trailing 12 Mt.) 3.64
- Price/Book (Most Recent Quarter) 28.86
- Enterprise Value Revenue 3.65
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.50
- Next Year EPS Estimate -$0.38
- Next Quarter EPS Estimate -$0.47
- Profit Margin -203%
- Operating Margin -178%
- Return on Assets -30%
- Return on Equity -292%
- Revenue 49.12 million
- Earnings Per Share -$2.61
- Revenue Per Share $1.02
- Gross Profit 41.6 million
- Quarterly Earnings Growth 47.5%
Highlights
- Market Capitalization 205.43 million
- EBITDA -100123000
- PE Ratio -3.83
- Analyst Target Price $16
- Book Value Per Share $0.13
Share Statistics
- Shares Outstanding 52.95 million
- Shares Float 32.04 million
- % Held by Insiders 896%
- % Held by Institutions 94.42%
- Shares Short 4.78 million
- Shares Short Prior Month 4.72 million
- Short Ratio 9.89
- Short % of Float 16%
- Short % of Shares Outstanding 9%
Technicals
- Beta 1.02
- 52 Week High $7.1
- 52 Week Low $3.14
- 50 Day Moving Average 4.1
- 200 Day Moving Average 4.13
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
OptiNose, Inc (OPTN) Dividend Calendar:
OptiNose, Inc (OPTN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
OptiNose, Inc (OPTN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
OptiNose, Inc (OPTN) Chart:
OptiNose, Inc (OPTN) News:
Below you will find a list of latest news for OptiNose, Inc (OPTN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
OptiNose, Inc (OPTN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest OPTN Trades:
OptiNose, Inc (OPTN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-22 | 8-K (Current report) | |
| 2020-10-07 | 8-K (Current report) | |
| 2020-09-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-21 | 8-K (Current report) | |
| 2020-09-17 | 8-K (Current report) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-19 | D (Notice of Exempt Offering of Securities) | |
| 2020-08-18 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-18 | 8-K (Current report) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-04 | 8-K (Current report) | |
| 2020-08-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
OptiNose, Inc (OPTN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of OptiNose, Inc (OPTN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 896%
Institutional Ownership: 9442%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-23 | Keith A. Goldan | Chief Financial Officer | Buy | 2,500.00 | 3.90 | 9,742.50 | 9,751.00 | |
| 2020-09-04 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 1,000.00 | 4.25 | 4,250.00 | 17,570.00 | |
| 2020-09-01 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 1,000.00 | 4.30 | 4,300.00 | 16,570.00 | |
| 2020-08-21 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 1,000.00 | 5.03 | 5,030.00 | 15,570.00 | |
| 2020-08-20 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 1,000.00 | 5.25 | 5,250.00 | 14,570.00 | |
| 2020-08-18 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 500.00 | 5.10 | 2,550.00 | 13,003.00 | |
| 2020-08-17 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 1,000.00 | 5.26 | 5,260.00 | 11,503.00 | |
| 2020-08-17 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 1,000.00 | 5.15 | 5,150.00 | 12,503.00 | |
| 2020-08-14 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 2,000.00 | 5.13 | 10,260.00 | 10,503.00 | |
| 2020-08-14 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 567.00 | 5.01 | 2,840.67 | 13,570.00 | |
| 2020-08-14 | Michael F III Marino | Chief Legal Officer & Corp Sec | Buy | 1,000.00 | 5.10 | 5,100.00 | 8,503.00 | |
| 2020-08-11 | Peter K Miller | Chief Executive Officer | Sell | 4,138.00 | 7.00 | 28,982.55 | 142,089.00 | |
| 2020-08-11 | Peter K Miller | Chief Executive Officer | Buy | 11,988.00 | 1.63 | 19,540.44 | 146,227.00 | |
| 2020-08-11 | Ramy A Mahmoud | President and COO | Sell | 1,678.00 | 7.00 | 11,752.71 | 3,889.00 | |
| 2020-08-11 | Ramy A Mahmoud | President and COO | Buy | 4,861.00 | 1.63 | 7,923.43 | 5,567.00 | |
| 2020-08-11 | Peter K Miller | Chief Executive Officer | Sell | 2,562.00 | 7.00 | 17,944.25 | 5,938.00 | |
| 2020-08-11 | Ramy A Mahmoud | President and COO | Sell | 5,022.00 | 7.00 | 35,174.09 | 67,246.00 | |
| 2020-08-11 | Ramy A Mahmoud | President and COO | Buy | 14,549.00 | 1.63 | 23,714.87 | 72,268.00 | |
| 2020-08-11 | Peter K Miller | Chief Executive Officer | Buy | 7,425.00 | 1.63 | 12,102.75 | 8,500.00 | |
| 2020-08-10 | Ramy A Mahmoud | President and COO | Sell | 580.00 | 7.00 | 4,060.00 | 1,102.00 | |